Biomarker Discovery in Chronic Graft-vs-Host Disease

慢性移植物抗宿主病的生物标志物发现

• 批准号: 8081764
• 负责人: John Andrew Hansen
• 金额: $ 44万
• 依托单位: FRED HUTCHINSON CANCER RESEARCH CENTER
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-07-17 至 2012-12-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8081764
• 关键词: Address; Allogenic; Alternative Splicing; Ancillary Study; Antibodies; Biological Assay; Biological Markers; Candidate Disease Gene; Caring; Case-Control Studies; Chronic; Clinical; Clinical Trials; Cohort Studies; Consent; Consent Forms; Dana-Farber Cancer Institute; Development; Diagnosis; Diagnostic; Disease; Effectiveness; Enrollment; Exons; Family; Fred Hutchinson Cancer Research Center; Funding; Gene Expression; Goals; Grant; Health care facility; Hematopoietic Stem Cell Transplantation; Human; Immunosuppression; Institutional Review Boards; Letters; Mass Spectrum Analysis; Methods; Minnesota; Modification; Monitor; Mononuclear Leukocytes; Morbidity - disease rate; Outcome Assessment; Participant; Patients; Peripheral Blood Mononuclear Cell; Phase; Physicians; Plasma; Proteins; Proteomics; Protocols documentation; Research Personnel; Resolution; Sampling; Sampling Studies; Sensitivity and Specificity; Severities; Site; Staging; Study Subject; Survivors; Symptoms; Therapeutic Intervention; United States National Institutes of Health; Universities; Validation; Variant; abstracting; base; cancer care; candidate validation; chronic graft versus host disease; disorder control; genome-wide analysis; graft vs host disease; improved; innovative technologies; insight; mortality; novel; peripheral blood; response; sample collection; tool; treatment response; treatment strategy; validation studies; willingness

DESCRIPTION (provided by applicant): Chronic graft-versus-host disease (cGVHD) occurs in 50-70% of patients following allogeneic hematopoietic stem cell transplantation (HSCT) and is a major cause of morbidity and mortality. The clinical manifestations of cGVHD are diverse and variable, and the diagnosis, staging and assessment of response to therapeutic interventions have been difficult to standardize. There are no signs or symptoms or diagnostic tools that predict the development or severity of cGVHD, or the need for immune suppression therapy. The goal of this proposal is to address these unmet needs by identifying novel biomarkers that are associated with the onset and severity of cGVHD. The initial phase of study will consist of a parallel discovery strategy that employs a genome-wide analysis of transcriptional changes in peripheral blood mononuclear cells (PBMC) together with a high-resolution, high-sensitivity quantitative proteomic analysis to identify informative proteins in plasma that correlate with disease activity. These transcriptional changes and proteins will be prioritized to develop a list of candidates for second phase validation studies to confirm and further define a panel of markers that together provide high sensitivity and specificity for the diagnosis of cGVHD and the prediction of severity and/or treatment response. Aim 1 of this study is to identify novel biomarkers in peripheral blood for the diagnosis of cGVHD using dual approaches: 1a) analysis of global gene expression and alternate splicing in mononuclear leucocytes; and 1b) quantitative in-depth profiling of circulating proteins in plasma. The transcriptional analysis will be performed on PBMC using the Affymetrix Human Exon 1.0 ST array, and the proteomic analysis will be performed on plasma by mass spectrometry. Aim 2 will focus on the validation of candidate biomarkers identified in an independent, multicenter cohort study of cGVHD. Candidate genes and alternate splice variants will be validated by PCR-based assays, and candidate proteins will be validated by antibody-based assays. This application is submitted in response to RFA-HL-08-001, titled "Ancillary Studies in Clinical trials (R01)." We are proposing a biomarker discovery and validation project that is focused on cGVHD occurring after allo HSCT. The subjects for this study, cases and controls, will be enrolled in a separate NIH funded multi-center study titled "Improving outcomes assessment in chronic GVHD" (R01-CA118953; Dr. Stephanie Lee, PI). Participating Centers include the Dana-Farber Cancer Institute (DFCI), the Seattle Cancer Care Alliance (SCCA)/Fred Hutchinson Cancer Research Center (FHCRC), Stanford University and the University of Minnesota. Total enrollment across the sites will reach 336 incident and 336 prevalent cGVHD cases. Patients will be followed for three years, and systematically evaluated for cGVHD status and response to cGVHD therapy. Chronic graft-versus-host disease (cGVHD) occurs in 50-70% of patients following allogeneic hematopoietic stem cell transplantation (HSCT) and is a major cause of morbidity and mortality. As the utilization of HSCT and number of HSCT survivors increases, the issue of cGVHD becomes a greater concern not only to patients and their families but also to the specialized physicians and health care facilities responsible for their care. The studies proposed here are aimed at improving methods for the diagnosis of cGVHD, monitoring disease activity and the effectiveness of cGVHD therapy. These studies may also yield insights into the underlying disorders responsible for cGVHD and thereby suggest new treatment strategies. (End of Abstract)

描述（由申请人提供）：

项目成果

A combined biomarker and clinical panel for chronic graft versus host disease diagnosis.

用于慢性移植物与宿主疾病诊断的合并生物标志物和临床面板。

• DOI: 10.1002/cjp2.58
• 发表时间: 2017-01
• 期刊: The journal of pathology. Clinical research
• 作者: Pidala J;Sigdel TK;Wang A;Hsieh S;Inamoto Y;Martin PJ;Flowers ME;Hansen JA;Lee SJ;Sarwal MM
• 通讯作者: Sarwal MM